Literature DB >> 12370993

Pathogenesis of nontuberculous mycobacteria infections.

Jeffery McGarvey1, Luiz E Bermudez.   

Abstract

M avium is a microorganism well adapted to living in the environment and in different hosts. During the past 15 years, a substantial amount of information has been accumulated about the mechanisms used by M avium to cross the host's mucosal barrier, replicate inside cells, circumvent the host's immune response, and persist inside the host. It turns out that M avium is a fascinating pathogen after all. The increasing knowledge about M avium pathogenesis may one day provide means for a more effective prophylaxis as well as for treatment of the infection.

Entities:  

Mesh:

Year:  2002        PMID: 12370993     DOI: 10.1016/s0272-5231(02)00012-6

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  18 in total

1.  Evaluation of a modified single-enzyme amplified-fragment length polymorphism technique for fingerprinting and differentiating of Mycobacterium kansasii type I isolates.

Authors:  Ayman Gaafar; M Josebe Unzaga; Ramón Cisterna; Felicitas Elena Clavo; Elena Urra; Rafael Ayarza; Gloria Martín
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Surface proteome of "Mycobacterium avium subsp. hominissuis" during the early stages of macrophage infection.

Authors:  Michael McNamara; Shin-Cheng Tzeng; Claudia Maier; Li Zhang; Luiz E Bermudez
Journal:  Infect Immun       Date:  2012-03-05       Impact factor: 3.441

4.  Tuberculous otitis media developing as a complication of tympanostomy tube insertion.

Authors:  Chang Woo Kim; Jae Won Jin; Young-Soo Rho
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-09-21       Impact factor: 2.503

5.  Virulence and immune response induced by Mycobacterium avium complex strains in a model of progressive pulmonary tuberculosis and subcutaneous infection in BALB/c mice.

Authors:  Mónica González-Pérez; Leonardo Mariño-Ramírez; Carlos Alberto Parra-López; Martha Isabel Murcia; Brenda Marquina; Dulce Mata-Espinoza; Yadira Rodriguez-Míguez; Guillermina J Baay-Guzman; Sara Huerta-Yepez; Rogelio Hernandez-Pando
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

6.  Mycobacterium avium serovars 2 and 8 infections elicit unique activation of the host macrophage immune responses.

Authors:  B R Cebula; J M Rocco; J N Maslow; V R Irani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-19       Impact factor: 3.267

7.  Identification of Mycobacterium avium pathogenicity island important for macrophage and amoeba infection.

Authors:  Lia Danelishvili; Martin Wu; Bernadette Stang; Melanie Harriff; Suat L G Cirillo; Stuart Cirillo; Jeffrey D Cirillo; Jeffrey Cirillo; Robert Bildfell; Brian Arbogast; Luiz E Bermudez
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

Authors:  Luiz E Bermudez; Peter Kolonoski; Lianne E Seitz; Mary Petrofsky; Robert Reynolds; Martin Wu; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Nontuberculous mycobacterial infections among patients suspected of pulmonary tuberculosis.

Authors:  H Grubek-Jaworska; R Walkiewicz; A Safianowska; M Nowacka-Mazurek; R Krenke; T Przybyłowski; R Chazan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-14       Impact factor: 3.267

Review 10.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.